Purgo Biologics Inc. is a South Korean biomaterials company with over 20 years of expertise in the development and manufacturing of dental regenerative solutions, with a primary focus on bone graft substitutes and barrier membranes. Guided by its core principle, "Leading the New Standard of Regeneration," the company pursues the advancement of clinically reliable and biologically optimized materials designed to support predictable regenerative outcomes in dental applications.

Based on these clinical results, Purgo has published over 80 scientific papers, including those in SCI-level journals, and has proven its product excellence through regulatory approvals in more than 50 countries.

The company’s flagship product, THE Graft (porcine-derived xenograft), is recognized for its favorable clinical efficacy and superior biological performance. Building on this success, THE Graft Collagen (porcine-derived xenograft with collagen) achieved a significant milestone by becoming the first in South Korea and the second worldwide in its category to receive certification under the European Union Medical Device Regulation (EU MDR).

Purgo continues to strengthen its position as a leading global innovator in dental biomaterials by expanding its comprehensive product portfolio, which includes advanced bone grafts, membranes, and sutures.